Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTIFY: Certolizumab for unexplained recurrent implantation failure
2021-005309-28Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Feb 2023
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Recurrent Implantation Failure (RIF) comparing Certolizumab pegol with Placebo (2 arms). Primary endpoint: Clinical pregnancy rate. Started Feb 2023; status: active.
02
Drugs
certolizumab pegol
03
Conditions
Recurrent Implantation Failure (RIF)
Beyond the preview
Go deeper on 2021-005309-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005309-28.